에 대한 최신 뉴스 CureVac (NASDAQ:CVAC) 주식

CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Injecting,Injection,Vaccine,Vaccination,Medicine,Into,A,Syringe,Woman,Nurse

Biotech

Equities

Government

News

Regulations

Health Care

Politics

Markets

CVAC

MRNA

NVAX

도널드 트럼프 행정부가 모더나(NASDAQ:MRNA)와 mRNA 기반 조류독감 백신 개발을 위한 거의 6억 달러에 달하는 계약을 해지했다. 이는 조 바이든 시대의 주요 팬데믹 대비 이니셔티브를 종료하는 것이다.

트럼프 행정부, 5억 9천만 달러 규모의 모더나 조류독감 백신 계약 해지···바이든의 전염병 대비 노력 해체

Virus,Sample,For,H5n1,(avian,Influenza,Virus),Test,,Avian,Influenza

Large Cap

General

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 보도했다. 미국 질병통제예방센터(CDC)는 월요일에 초기 양성 반응을 확인하기 위해 작업 중이다.

네바다 남성에서 발견된 치명적인 조류 독감 변종: 주목해야 할 4가지 주식

CureVac NV

<ul>
<li>Real-world claims studies evaluating UZEDY&#xAE; (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options</li>
<li>Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date</li>
<li>As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia</li>
</ul>

TEVA

Reported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics

The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax&#xAE;), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.

Reported Saturday, mNEXSPIKE Becomes FDA-Approved: Moderna's New COVID-19 Vaccine Shows Higher Efficacy vs. Spikevax In Phase 3 Trial

<ul>
<li>26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases</li>
<li>Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms</li>
<li>MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C (combination dose escalation) remains on treatment after more than 14 months</li>
<li>Combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events</li>
</ul>

Reported Saturday, Xilio's Tumor-Activated Anti-CTLA-4 Vilastobart Shows 26% Objective Response Rate With Durable Responses And Low Colitis In MSS CRC Without Liver Metastases

<ul>
<li>Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to &gt;2.5 years &nbsp;</li>
<li>IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months 
<ul>
<li>Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months</li>
<li>Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS of 8.5 months &nbsp;</li>
</ul>
</li>
<li>Positive Phase 1b data and high PRAME prevalence in melanoma reinforce the basis for the ongoing SUPRAME Phase 3 trial in previously treated advanced or metastatic cutaneous melanoma, as well as the continued Phase 1b expansion in uveal melanoma &nbsp;</li>
<li>ASCO presentations further substantiate Immatics' global leadership in precision targeting of PRAME and potential of IMA203 to be the Company's first PRAME product &nbsp;</li>
</ul>

IMTX

Reported Saturday, Immatics Presents Expanded IMA203 PRAME Cell Therapy Results At ASCO: Durable Objective Responses In 91% Of Patients And Favorable Safety Profile

A new study has warned that declining childhood vaccination rates in the United States could trigger a dramatic resurgence of diseases that were eradicated years ago.
What Happened: On Sunday, former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb shared a study on X highlighting the consequences of America&#8217;s turn towards vaccine skepticism, and a policy framework that is increasingly enabling the same.
While sharing a study titled Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination, Gottlieb quotes from it, saying, &#8220;at current vaccination rates, measles may become endemic again.&#8221;
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45715155/elizabeth-warren-calls-it-textbook-corruption-once-again-asks-for-probe-into-elon-musk-cashing-in-on-trump-tariffs">Elizabeth Warren Calls It &#8216;Textbook Corruption,&#8217; Once Again Asks For Probe Into Elon Musk &#8216;Cashing In&#8217; On Trump Tariffs</a>
He highlighted the staggering projections from the study, &#8220;51.2 [million] measles cases over a 25-year period, 9.9 [million] rubella cases, 4.3 [million] poliomyelitis cases, 197 diphtheria cases, 10.3 [million] hospitalizations, and 159,200 deaths.&#8221;
The Stanford University study&#8217;s projections are based on a scenario in which vaccine uptake drops 50%, at which point it finds that measles alone could reach endemic levels within just 5 years. 
Even at current vaccination levels, the study estimates an 83% chance of measles returning to endemicity within two decades.
The study also projects 9.9 million rubella cases, 4.3 million polio cases, and nearly 11,000 instances of congenital rubella syndrome in the event of steep declines in vaccination. The forecast includes as many as 5,400 cases of paralytic polio, a disease declared eliminated in the U.S. in 1979.
These findings come amid rising anti-vaccine sentiments in the country, alongside proposed <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">policy rollbacks</a> on vaccine mandates. 
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">‘At current vaccination rates, measles may become endemic again… a US simulation model predicted 51.2M measles cases over a 25-year period, 9.9M rubella cases, 4.3M poliomyelitis cases, 197 diphtheria cases, 10.3M hospitalizations, and 159,200 deaths'<a href="https://t.co/kSDWqTRvhb">https://t.co/kSDWqTRvhb</a>
&mdash; Scott Gottlieb, MD &#x1f1fa;&#x1f1f8; (@ScottGottliebMD) <a href="https://twitter.com/ScottGottliebMD/status/1929201297674088748?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The Health and Human Services Secretary (HHS), Robert F. Kennedy Jr, has come under increasing scrutiny for spreading vaccine misinformation. 
Last week, a senior vaccine official at the FDA, Peter Marks, resigned <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">from his position</a>, while accusing Kennedy of actions that were harmful to public health.
This also comes amid extensive <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">budget and job cuts</a> at the federal healthcare department, which includes the FDA, the National Institute of Health, and the Centers for Disease Control and Prevention, which could impair the ability of these agencies to perform their tasks effectively. 
See Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714416/former-treasury-secretary-larry-summers-warns-the-dollar-is-starting-to-trade-like-a-latin-american-currency-greenback-going-from-safe-haven-to-risk-asset">Former Treasury Secretary Larry Summers Warns The Dollar Is Starting To Trade Like A Latin American Currency — Greenback Going From Safe Haven To Risk Asset?</a></li>
</ul>
Photo courtesy: Shutterstock

51.2 Million Measles Cases, 159,200 Deaths: New Study Warns Of Surge In Preventable Diseases Amid Growing Vaccine Skepticism

<ul>
<li>BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status</li>
<li>At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data</li>
</ul>

Reported Saturday, BeOne's SEQUOIA Trial Shows BRUKINSA Plus Venetoclax Yields Deep, Durable Responses Across CLL Risk Groups Including del(17p) And TP53

Macro Economic Events

Econ #s

Economics

U.K. Manufacturing Purchasing Managers Index For May 46.4 Vs. 45.1 Est.; 45.4 Prior

Broad Arrow Auctions, a Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) company, is delighted to announce the addition of a new event on its global auction calendar—The Zoute Concours Auction, held in collaboration with Zoute Grand Prix Car Week (8-12 October 2025) in Belgium. Set for Friday, 10 October on the grounds of the beautiful Approach Golf in Knokke-Heist, a stone's throw from the beach, the single-day auction will present approximately 70 exceptional collector cars across a wide variety of categories, marques, and price points.

HGTY

Hagerty's Broad Arrow Adds Belgium Auction Featuring 70 Classic Cars at Zoute Grand Prix

<h3>Companies Reporting Before The Bell</h3>
• The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $2.43 billion. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is estimated to report quarterly earnings at $2.12 per share on revenue of $1.87 billion. 
<h3>Companies Reporting After The Bell</h3>
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $159.59 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CRDO

SAIC

Earnings Scheduled For June 2, 2025

U.S. President Donald Trump has announced the withdrawal of Jared Isaacman's nomination for the NASA administrator job due to Isaacman's "prior associations."
What Happened: "After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA," Trump said in a post on Truth Social on Saturday.
The president then went on to say that he would announce a new nominee soon, who would be more "Mission aligned, and put America First in Space," Trump said.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="361" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg" alt="" class="wp-image-934652" style="width:484px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-300x106.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-768x271.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social.jpg 1211w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
source: Truth Social
Isaacman has donated to the Democratic Party in prior elections, as the <a href="https://www.opensecrets.org/donor-lookup/results?name=Jared+Isaacman&amp;order=desc&amp;sort=D">data</a> from the non-profit organization OpenSecrets showcases the Shift4 CEO donating to a candidate from the party.&nbsp;
Why It Matters: The news comes in just days after billionaire Elon Musk's exit from the Trump administration's DOGE, or Department of Government Efficiency. The president also hosted <a href="https://www.benzinga.com/news/25/05/45707423/trump-says-he-is-having-elon-musk-over-at-the-white-house-tomorrow-for-a-press-conference-as-billion">Musk at the White House</a>.
Isaacman's withdrawal by Trump casts uncertainty over NASA's commitment to Mars exploration, something that Isaacman had <a href="https://www.benzinga.com/general/space/25/04/44730104/trumps-nasa-chief-pick-isaacman-tells-senate-we-will-prioritize-sending-american-astronauts-to-mars">doubled down on</a> in the past and is a major target for Musk's SpaceX.
SpaceX recently held a test launch for its Starship rocket from a launch site in Texas. However, the launch failed as the <a href="https://www.benzinga.com/general/space/25/05/45636692/elon-musks-mars-ambitions-face-new-setback-as-spacex-starship-test-flight-fails">rocket spun out of control </a>30 minutes into the mission after it was launched in suborbital space.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45637814/elon-musk-admits-he-spent-too-much-time-on-politics-after-tesla-sales-decline-in-multiple-regions">Elon Musk Admits He Spent &#8216;Too Much Time&#8217; On Politics After Tesla Sales Decline In Multiple Regions</a></li>
</ul>
Photo courtesy: Pandora Pictures / Shutterstock.com

SPACE

Donald Trump Withdraws Jared Isaacman's Nomination For NASA Administrator, Says New Nominee Would 'Put America First in Space'

<ul>
<li>Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation</li>
<li>Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events</li>
<li>Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer</li>
<li>Data to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of Medicine</li>
</ul>

ARVN

Reported Saturday, Arvinas and Pfizer's Vepdegestrant Demonstrates Statistically Significant 2.9-Month PFS Benefit Over Fulvestrant In ESR1-Mutant Second-Line Advanced Breast Cancer

The Trump administration has reportedly been discreetly working with&nbsp;Palantir Technologies Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) to gather personal data of American citizens from various federal agencies, sparking concerns over privacy and potential misuse of personal data.
What Happened: President Trump&#8217;s March executive order for federal data sharing is being implemented through Palantir&#8217;s product, Foundry. Although Trump has not publicly discussed this initiative, this platform is already in use by several federal agencies, including the Department of Health and Human Services as well as the Social Security Administration, <a href="https://www.nytimes.com/2025/05/30/technology/trump-palantir-data-americans.html">reported</a> The New York Times on Friday.
Foundry&#8217;s capabilities in data organization and analysis could potentially enable the merging of information from various agencies, thereby creating detailed profiles of American citizens. The Trump administration has attempted to access extensive citizen data from government databases, including bank details, student debt, medical claims, and disability status.
Palantir did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Palantir&#8217;s selection as a primary vendor for this project was reportedly influenced by the Department of Government Efficiency (DOGE), which was being overseen by&nbsp;Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO, Elon Musk.&nbsp;
Critics, including Democratic lawmakers and privacy advocates, fear that such data could be exploited for political purposes, such as policing immigrants and targeting critics.
Some Palantir employees fear the company&#8217;s association with Trump&#8217;s agenda and potential data breaches, prompting 13 former staffers to sign a letter urging it to cut ties with the administration.
SEE ALSO:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713694/mypillow-guy-mike-lindell-reportedly-plans-to-testify-at-his-defamation-trial-i-have-nothing-to-hide-i-a" target="_blank" rel="noreferrer noopener">MyPillow Guy Mike Lindell Reportedly Plans To Testify At His Defamation Trial: &#8216;I Have Nothing To Hide. I Am A Former Crack Addict&#8217;</a>
Why It Matters: The Trump administration&#8217;s collaboration with Palantir comes on the heels of several significant developments for the company. In late May, the Department of Defense (DoD) awarded Palantir a $795 million <a href="https://www.benzinga.com/25/05/45572000/palantir-stock-is-trading-higher-thursday-whats-going-on">modification to a contract</a> for its Maven Smart System software licenses, which likely contributed to a surge in the company&#8217;s stock price.
Earlier that month, Palantir announced a <a href="https://www.benzinga.com/markets/equities/25/05/45536259/palantir-partners-with-sap-to-fuse-ontology-foundry-and-enterprise-dataceo-alex-karp-calls-it-extremely-valuable">strategic partnership</a> with enterprise software giant&nbsp;SAP SE&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>), integrating its data platforms with SAP&#8217;s enterprise solutions, a move that CEO&nbsp;Alex Karp&nbsp;described as &#8220;extremely valuable.&#8221;
Benzinga's Edge Rankings place Palantir in the 97th percentile for quality and the 3rd percentile for value, reflecting its mixed performance. Check the detailed report <a href="https://www.benzinga.com/quote/PLTR">here</a>.&nbsp;
The shares of Palantir climbed 7.73% to close at 131.78 on Friday. On a year-to-date basis, it surged 75.26%.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45714198/elon-musks-kekius-maximus-gameplay-sends-these-namesake-coins-surging" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;Kekius Maximus&#8217; Gameplay Sends These Namesake Coins Surging</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

PLTR

TSLA

Trump Administration Silently Employs Palantir To Gather Personal Data Of Each American, Raising Privacy, Data Misuse Concerns: Report

<ul>
<li>Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p&lt;0.0001)</li>
<li>Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo&nbsp;&nbsp;</li>
<li>Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine</li>
<li>Regulatory applications have been submitted in the United States and European Union</li>
</ul>

REGN

Reported Saturday, Regeneron's Libtayo Demonstrates Practice-Changing Results In Adjuvant High-Risk Cutaneous Squamous Cell Carcinoma With 87% Two-Year Disease-Free Survival

<ul>
<li>The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone –</li>
<li>The PIK3CA mutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis –</li>
<li>New data are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine</li>
</ul>

RHHBF

RHHBY

Reported Saturday, Genentech's Itovebi-Based Regimen Cuts Risk Of Death By Over 30% In PIK3CA-Mutated HR-Positive, HER2-Negative Advanced Breast Cancer, Phase III INAVO120 Data Show

President Donald Trump&#8216;s artificial intelligence advisor, David Sacks, criticized former President Barack Obama&#8216;s recent warnings <a href="https://www.benzinga.com/markets/25/05/45486440/david-sacks-hails-trumps-ai-strategy-in-middle-east-as-power-move-over-china-openai-ceo-sam-altman-backs-him-sorry-naive-people-are-giving-you-grief">about AI-driven job displacement</a>, characterizing them as part of a coordinated &#8220;influence operation&#8221; designed to advance &#8220;Global AI Governance&#8221; initiatives.
What Happened: In a series of posts on X, Sacks warned Republicans against accepting Obama&#8217;s &#8220;hyperbolic and unproven claims about AI job loss,&#8221; describing them as ammunition for what he termed a &#8220;massive power grab by the bureaucratic state and globalist institutions.&#8221;
The crypto czar specifically targeted &#8220;Effective Altruist&#8221; billionaires with histories of funding left-wing causes and opposing Trump.
Sacks responded to Andreessen Horowitz general partner Martin Casado, who praised coverage of Open Philanthropy&#8217;s alleged astroturfing campaign to regulate AI compute resources.
&#8220;There is much much more going on that is either unknown or chronically underdiscussed,&#8221; Casado noted, highlighting what he characterized as coordinated efforts to restrict AI development.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Republicans should understand that when Obama retweets hyperbolic and unproven claims about AI job loss, it's not an accident, it's part of an influence operation. The goal: to further "Global AI Governance," a massive power grab by the bureaucratic state and globalist… <a href="https://t.co/1cURrzzSL5">https://t.co/1cURrzzSL5</a>
&mdash; David Sacks (@DavidSacks) <a href="https://twitter.com/DavidSacks/status/1929276589566562358?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Sacks emphasized the fundamental ideological divide, stating these actors &#8220;fundamentally believe in empowering government to the maximum.&#8221; He warned that &#8220;the single greatest dystopian risk associated with AI is the risk that government uses it to control all of us,&#8221; potentially creating an &#8220;Orwellian future where AI is controlled by the government.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/cannabis/25/06/45713895/bitcoin-ethereum-dogecoin-hold-steady-amid-us-china-trade-war-tensions-analyst-foresees-big-party-if-btc-reclaims-106000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Hold Steady Amid US-China Trade War Tensions: Analyst Foresees ‘Big Party' If BTC Reclaims $106,000</a>
Why It Matters: This pivot follows what industry observers call the &#8220;DeepSeek moment,&#8221; when China&#8217;s breakthrough AI model demonstrated significant capabilities, challenging Western assumptions about Chinese AI development. 
The controversy highlights tensions between rapid AI advancement and governance frameworks. Hedge fund manager Paul Tudor Jones recently warned that <a href="https://www.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous">leading AI modelers believe there&#8217;s a 10% chance</a> AI could &#8220;kill 50% of humanity&#8221; within 20 years, yet security spending remains minimal compared to $250 billion in development investments by major tech companies.
Sacks concluded his analysis by warning that &#8220;WokeAI + Global AI Governance = the most Orwellian future imaginable,&#8221; positioning this combination as the ultimate goal of Effective Altruist organizations seeking expanded regulatory control over AI development and deployment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45714095/chamath-palihapitiya-calls-tesla-an-obvious-win-says-robotaxi-alphabets-waymo-will-overtake-uber-and-lyft" target="_blank" rel="noreferrer noopener">Chamath Palihapitiya Calls Tesla An ‘Obvious Win,' Says Robotaxi, Alphabet's Waymo Will Overtake Uber And Lyft</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Tapati Rinchumrus on Shutterstock.com

Obama's AI Job Loss Warnings Aren't Accidental, Says David Sacks: They're Fueling A Global Power Grab And 'The Most Orwellian Future Imaginable'

<ul>
<li>TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial</li>
<li>The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer</li>
<li>Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology</li>
</ul>

NVCR

ZLAB

Reported Sunday, Zai Lab And Novocure Announce PANOVA-3 Results: TTFields Therapy Achieves Median OS Of 16.2 Months With Significant Gains In Quality Of Life And Pain Control

The U.S. Commerce Secretary, Howard Lutnick, doubles down on the Trump administration&#8217;s tariff strategy following recent federal court rulings that blocked key trade policies, declaring America&#8217;s trade deficit a national emergency requiring immediate action.
What Happened: In a Fox News interview <a href="https://www.youtube.com/watch?v=t0UtSmEWhbw">on</a> Sunday, Lutnick outlined the legal framework supporting continued tariff implementation. &#8220;The $1.2 trillion trade deficit, and all the underlying implications of that, is a National Emergency — it&#8217;s gutting our manufacturing base&#8230; rest assured, tariffs are not going away,&#8221; Lutnick stated.
Lutnick emphasized that Congress granted President Donald Trump authority under the International Emergency Economic Powers Act (IEEPA) to address countries creating national emergencies. 
&#8220;Congress has given this authority to Trump, and he&#8217;s going to use it,&#8221; he said, indicating multiple legal pathways remain available even if current challenges succeed in higher courts.
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45714519/ross-ulbricht-the-silk-road-founder-pardoned-by-trump-soon-after-his-inauguration-receives-a-whopping-31-million-worth-of-bitcoin-in-donation-wallet">Ross Ulbricht, The Silk Road Founder Pardoned By Trump Soon After His Inauguration, Receives A Whopping $31 Million Worth Of Bitcoin In Donation Wallet</a>
Why It Matters: Lutnick&#8217;s comments come as federal courts have blocked significant portions of Trump&#8217;s tariff program. U.S. District Judge Rudolph Contreras ruled <a href="https://www.benzinga.com/25/05/45687946/second-federal-judge-blocks-trumps-emergency-tariff-powers-hours-after-us-court-of-international-trade-ruling">IEEPA does not grant Trump authority to impose tariffs</a> without Congressional approval. 
The U.S. Court of International Trade separately struck down 6.7 percentage points of tariffs, potentially <a href="https://www.benzinga.com/news/25/05/45707793/tariffs-blocked-by-court-but-goldman-sachs-says-trump-could-reimpose-them-within-days">affecting $200 billion </a>in annual revenue.
Goldman Sachs economist Alec Phillips noted the administration could quickly reimpose similar tariffs using Section 122 authority, which allows 15% tariffs for 150 days without Congressional approval. 
The Kobeissi Letter <a href="https://www.benzinga.com/government/regulations/25/05/45667775/trumps-tariff-refund-could-cost-us-10-billion-with-2-month-end-rebalance-impact-on-equities-in-case-of-an-appeal-uncertainty-is-back-front-and-center">estimates that approximately $10 billion</a> in tariff revenue has been collected since April 2, which could require refunding if court rulings are upheld.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714416/former-treasury-secretary-larry-summers-warns-the-dollar-is-starting-to-trade-like-a-latin-american-currency-greenback-going-from-safe-haven-to-risk-asset">Former Treasury Secretary Larry Summers Warns The Dollar Is Starting To Trade Like A Latin American Currency — Greenback Going From Safe Haven To Risk Asset?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Miha Creative via Shutterstock

Legal

Howard Lutnick Calls $1.2 Trillion Trade Deficit A 'National Emergency,' Says Trump's Tariffs Are 'Not Going Away'

Fundstrat&#8217;s Tom Lee has been betting on a &#8220;new bull market&#8221; following the spike in the volatility gauge in April, while another analyst believes that it is the &#8220;TACO&#8221; trade that is fueling the &#8220;run it hot&#8221; optimism in the market.
What Happened: According to Lee, the April lows were a &#8220;huge liquidation event,&#8221; as the CBOE VIX Index, or the fear gauge, spiked to the 60 level and the market was &#8220;reset,&#8221; fueling &#8220;a new bull market.&#8221;
&#8220;I think we had what was a miniature bear market, but has essentially rebirthed the new bull market,&#8221; he <a href="https://www.cnbc.com/2025/05/30/tom-lee-says-the-april-selloff-rebirthed-a-new-bull-market-.html?__source=twitter%7Cpro&amp;taid=6839dcb51dc732000173796f&amp;utm_campaign=trueanthem&amp;utm_content=pro&amp;utm_medium=social&amp;utm_source=twitter">told</a> CNBC.
The head of research at Fundstrat Global Advisors also expects &#8220;pretty shallow&#8221; dips from here, advising investors to consider small-cap stocks other than the Magnificent 7.
&#8220;As I look at the second half, I think the small caps really have a strong case to be made, because as long as we move towards a tariff resolution, or the markets feel that way, then I think investors can actually start putting flows back into stocks other than the Mag Seven," Lee said.
While a Federal appeals court <a href="https://www.benzinga.com/news/legal/25/05/45683326/trump-tariffs-temporarily-preserved-as-appeals-court-pauses-lower-ruling">temporarily reinstated</a> Donald Trump&#8216;s tariffs after the Court of International Trade invalidated them, the growing tensions with China and the ongoing court hearing about tariffs could keep the market on edge. 
However, Bob Elliott of Unlimited Funds said in an X post that the &#8220;TACO&#8221; or &#8216;Trump Always Chickens Out&#8217; trade could pave the way for a &#8220;Run It Hot&#8221; economic environment, characterized by growth-oriented policies and sustained stimulus, further fueling market optimism.
Elliott&#8217;s post signaled a widespread belief that Trump's possible tariff rollbacks or extensions are not only predictable but also conducive to a pro-growth economic stance.
According to him, &#8220;consensus&#8221; reflects market sentiment that TACO is priced in, meaning investors anticipate Trump&#8217;s tariff retreats, especially now that he is embroiled in the legal battle over the validation of his levied tariffs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">TACO and Run It Hot are consensus at this point.
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1929147958139744440?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/politics/25/05/45691310/trump-tariff-uncertainty-enters-courts-experts-say-investors-should-expect-elevated-turbulence-amid-the-bullish-gridlock">Trump Tariff Uncertainty Enters Courts: Experts Say &#8216;Investors Should Expect Elevated Turbulence&#8217; Amid The Bullish &#8216;Gridlock&#8217; </a>
Why It Matters: On Friday, Trump accused China of violating an agreement with the U.S. to ease tariffs in his Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114596705340367716">post</a>. However, Trump did not specify the details of this violation.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="451" height="373" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030148/China-violation.png" alt="" class="wp-image-934642" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030148/China-violation.png 451w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030148/China-violation-300x248.png 300w" sizes="(max-width: 451px) 100vw, 451px" /></figure>
Treasury Secretary Scott Bessent on Sunday clarified that China was withholding critical minerals it agreed to release in a trade deal the country signed with U.S. negotiators last month in Geneva.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Friday. The SPY was down 0.11% at $589.39, while the QQQ declined 0.16% to $519.11, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of the S&amp;P 500, Dow Jones and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45688628/dells-ai-server-orders-hit-record-12-1-billion-in-q1-backlog-swells-to-14-4-billion-exceptionally-strong-demand">Dell&#8217;s AI Server Orders Hit Record $12.1 Billion In Q1, Backlog Swells To $14.4 Billion: &#8216;Exceptionally Strong Demand&#8217;<span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;">Jim Cramer Attributes Nvidia&#8217;s Premarket Dip To &#8216;Meme Money&#8217; Frenzy: &#8216;Just Small Motivated Shareholders Knocking It Down&#8217;</a></li>
</ul>
Photo courtesy: Joey Sussman / Shutterstock.com

Tom Lee Bets On 'A New Bull Market,' As Trump's Tariff Retreat Fuels 'TACO' Trade Amid 'Run It Hot' Optimism

<ul>
<li>Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP</li>
<li>Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP</li>
<li>Data featured as an oral presentation at the ASCO Annual Meeting</li>
<li>Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration</li>
<li>Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results</li>
</ul>

ACTU

Reported Saturday, Actuate's Elraglusib Meets Primary Endpoint In Phase 2 mPDAC Trial, Extending Median Overall Survival To 10.1 Months And Cutting Risk Of Death By 37%

Eurozone Manufacturing Purchasing Managers Index For May 49.4 Vs. 48.4 Est.; 49.0	Prior

Management

Press Releases

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

도널드 트럼프 행정부가 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)와 mRNA 기반 조류독감 백신 개발을 위한 <a href="//www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight"" target="_blank" rel="noopener">거의 6억 달러에 달하는 계약을 해지</a>했다. 이는 조 바이든 시대의 주요 팬데믹 대비 이니셔티브를 종료하는 것이다.
무슨 일 있었나: 보건복지부 관리들이 모더나의 조류독감 백신 개발 계약 5억 9,000만 달러를 취소했다고 수요일(28일) 발표했다.
모더나 CEO 스테판 뱅셀은 다음과 같이 말했다. "HHS의 자금 지원 중단으로 불확실성이 커졌지만, H5 조류 독감 백신의 1/2상 임상시험 중간 분석에서 관찰된 강력한 면역 반응과 안전성 프로필에 만족하며, 앞으로 이 프로그램을 위한 대체 경로를 모색할 것이다."
모더나는 약 300명의 성인을 대상으로 한 임상 시험에서 참가자들이 두 번째 백신 접종 후 3주 이내에 거의 98%의 면역력을 달성했으며, 대체로 내약성이 양호한 것으로 나타났다고 보고했다.
트럼프 행정부 관리들은 이전에 이전 행정부의 모든 계약을 검토하고 있다고 밝힌 바 있다. 로버트 F. 케네디 주니어가 이끄는 HHS는 mRNA 백신 지출에 대한 <a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight" target="_blank" rel="noopener">"바이든 행정부의 4년간의 감독 실패&#8221;</a>로 인해 검토가 필요하다고 비판했다. 
왜 중요한가: H5N1이 계속 확산됨에 따라 계약 해지는 팬데믹 대비를 위협한다. 생물의학첨단연구개발청은 가축과 조류에서 순환하는 변종에 대한 방어책을 마련하기 위해 1월에 자금을 지원했다. 이는 앞서 7월에 1억 7,600만 달러의 조류 독감 백신 개발 기금을 수여한 데 따른 것이다.
미국 질병통제예방센터는 <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing?utm_source=chatgpt.com" target="_blank" rel="noopener">2024년 이후 67건의 인간 조류독감 사례</a>를 확인했으며, 루이지애나에서 미국 내 첫 사망자가 보고되어 공중보건 위협이 계속되고 있음을 강조했다.
노바백스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)와 큐어백(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) 등 다른 백신 제조업체들도 조류 감 백신을 개발하고 있으며, 두 회사 모두 임상 시험 중이다.
사진 제공: pedro7merino via Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 <a href="https://www.cnn.com/2025/02/08/health/bird-flu-variant-nevada-human-case/index.html">보도</a>했다. 미국 질병통제예방센터(CDC)는 월요일에 <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says" target="_blank" rel="noopener" data-google-interstitial="false">초기 양성 반응</a>을 확인하기 위해 작업 중이다.
상세 내용: 초기 양성 반응을 보인 네바다의 낙농업자는 현재 결막염 또는 &#8220;핑크 아이&#8221;를 포함한 경미한 증상을 겪고 있으며, 이는 최근 인간 감염에서 흔히 나타나는 증상으로 보인다.
지난주 미국 농무부는 네바다주에 있는 6마리의 젖소가 <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says">조류 독감 D1.1 변종에 양성 반응</a>을 보였다고 밝혔다. 이는 H5N1 바이러스 변종이 소에서 처음으로 발견된 사례이다.
다음 읽기: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">팔란티어, 일론 머스크의 AI 챗봇 그록을 AIP에 추가하다</a>
CDC에 따르면 <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">현재 공공 보건</a> 위험은 낮다. 이 기관은 인플루엔자 감시 시스템을 사용하여 사람들에서 H5 조류 독감 활동을 모니터링하고 있다.
1월에 도널드 트럼프 대통령은 <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">CDC의 모든 커뮤니케이션을 중지하라고 명령</a>했다. 현재 CDC 웹사이트에는 &#8220;트럼프 대통령의 행정명령에 따라 수정 중이다&#8221;라는 배너가 표시되고 있다.
CDC는 지난 목요일에 2주 동안 중단되었던 주간 <a href="https://www.cdc.gov/mmwr/index2025.html?ACSTrackingID=USCDC_921-DM144964&amp;ACSTrackingLabel=This%20Week%20in%20MMWR:%20Vol.%2074,%20February%206,%202025&amp;deliveryName=USCDC_921-DM144964">과학 보고서</a>인 주간 질병 사망률 보고서를 다시 발표했다.
기타 사항: H5N1 조류 독감은 야생 조류와 가금류에서 계속 퍼지고 있다. 지난주에 퀸즈와 브롱크스 동물원에서 15마리의 조류가 조류 독감으로 사망했으며, 동물원 대변인은 &#8220;취약한 조류 종&#8221;이 보호 구역으로 옮겨졌다고 <a href="https://gothamist.com/news/bird-flu-suspected-in-deaths-across-multiple-species-at-queens-and-bronx-zoos">고다미스트(Gothamist)</a>에 밝혔다. 수의사들이 시, 주 및 연방 규제 기관과 협력하고 있다.
뉴욕 주지사 캐시 호컬은 퀸즈, 브루클린 및 브롱크스에서 조류 독감 사례가 발견된 후 뉴욕시, 웨스트체스터 및 롱아일랜드의 살아있는 가금류 시장을 폐쇄하라고 명령했다.
국가 신흥 특수 병원체 훈련 및 교육 센터에 따르면, 2022년 조류 독감 발생 이후 6천만 마리 이상의 가금류가 사망하거나 <a href="https://netec.org/2023/01/30/situation-report-highly-pathogenic-avian-influenza-ah5n1/">도살</a>되었습니다. 2024년 4분기에는 2천만 마리 이상의 산란용 닭이 도살되어 미국 가금류 산업에 큰 영향을 미쳤다.
주목할 주식: 또 다른 인간 조류 독감 사례가 발견된 것으로 보이면서, 투자자들은 조류 독감 백신과 관련된 다음 주식들을 주의 깊게 모니터링할 수 있다.
모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 1월에 미국 보건복지부로부터 mRNA 기반 인플루엔자 백신, 특히 조류 독감 백신 개발을 가속화하기 위해 추가로 5억 9천만 달러의 지원을 받았다.
GSK(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 2024년 7월에 큐어백 BV(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>)로부터 조류 독감 백신 후보에 대한 모든 권리를 인수하고 개발에 대한 1상/2상 연구를 시작했다. 노바백스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) 또한 임상 시험 중인 조류 독감 백신 후보가 있다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">포드4분기 보고서 발표 후 주가 하락: 세부사항</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

CureVac

뉴스

에 대한 최신 뉴스 CureVac (NASDAQ:CVAC) 주식

목요일, 5월 29, 2025

목요일, 2월 13, 2025

뉴스

파트너 / 기고자

벤징가 글로벌